openPR Logo
Press release

Age-related Macular Degeneration Market Size was ~USD 9,500 Million in 2022, estimated DelveInsight

06-12-2024 10:26 PM CET | Health & Medicine

Press release from: ABNewswire

Age-related Macular Degeneration Market Size was ~USD 9,500

DelveInsight's 'Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034' report deliver an in-depth understanding of the Age-related Macular Degeneration, historical and forecasted epidemiology as well as the Age-related Macular Degeneration market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Explore the intricate details of the Age-related Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Macular Degeneration Market Forecast. Click here to stay ahead in healthcare innovation @ Age-related Macular Degeneration Market Size [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Age-related Macular Degeneration Market Report

* June 2024:- Stealth BioTherapeutics Inc. - A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD).
* June 2024:- Outlook Therapeutics Inc .- Safety and Effectiveness of ONS-5010 Compared to Lucentis Registered in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHT. Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
* June 2024:- Hoffmann-La Roche - A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Portal).
* June 2024:- Kyowa Kirin Inc.- A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration.
* In the year 2022, the total prevalent cases of AMD were approximately 52,684,880 in the 7MM, which might increase at a decent CAGR by 2034.
* The US accounted for approximately 17,688,550 prevalent cases of AMD in the year 2022.
* The leading Age-related Macular Degeneration Companies such as Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics , and others.
* Promising Age-related Macular Degeneration Therapies such as NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101 , and others.

Delve deep into the Age-related Macular Degeneration Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Age-related Macular Degeneration Market Forecast. Click here to shape the future @ Age-related Macular Degeneration Epidemiology Insights [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Overview

Age-related Macular Degeneration (AMD) is a medical condition that affects the macula, the central part of the retina responsible for sharp, detailed vision. It is a leading cause of vision loss in older adults. AMD comes in two main forms: dry (atrophic) and wet (neovascular or exudative).

Age-related Macular Degeneration Epidemiology Insights

* Total Age-related Macular Degeneration Prevalent Cases
* Total Age-related Macular Degeneration Age-specific Cases
* Total Age-related Macular Degeneration Diagnosed Prevalent Cases
* Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by stages
* Total Age-related Macular Degeneration Geographic Atrophy Cases by Visual Impairment
* Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases

Navigate the complexities of the Age-related Macular Degeneration Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Age-related Macular Degeneration Market Forecast. Click here to get more insights @ Age-related Macular Degeneration Treatment Market [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Market Insights

Age-related Macular Degeneration is the most common cause of severe loss of eyesight among people aged 50 and older. It affects the central vision and, with it, the ability to see fine details. In AMD, a part of the retina called the macula get damaged. Medication can help reduce the progression of the illness and prevent vision loss.

Age-related Macular Degeneration Treatment Landscape

the best available treatment for AMD was photodynamic therapy-in which an intravenous drug (injected into a vein) and laser were used to seal off leaking blood vessels. Past studies have found that just 1 year after diagnosis, less than 15% of patients given this therapy alone retain 20/40 vision, and up to 40% decline to 20/200 vision. However, advances in medical research have identified the Vascular Endothelial Growth Factor (VEGF) as a key pathophysiological factor in the development of neovascular AMD, with an essential role in angiogenesis, vascular permeability, and inflammatory response. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function.

Age-related Macular Degeneration Market Size

According to the DelveInsight analysis, the United States accounted for the highest market size, with approximately 50% of the market share of Dry age-related Macular Degeneration (AMD) as compared to other countries of the 7MM in the year 2022. The Age-related Macular Degeneration market size of the 7MM is anticipated to increase in the forecast period due to expected launch of emerging therapies in the 7MM.

Unlock insights into the Age-related Macular Degeneration Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Age-related Macular Degeneration Market Forecast. Click here @ Age-related Macular Degeneration Market Drivers and Barriers [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Age-related Macular Degeneration Therapies and Companies

* Eylea (aflibercept): Regeneron Pharmaceuticals
* Beovu(brolucizumab): Novartis
* Lucentis (ranibizumab): Roche
* Vabysmo (faricimab): Roche
* Susvimo (ranibizumab): Roche

Age-related Macular Degeneration Drug Market

The overall Age-related Macular Degeneration (AMD) Market is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2024-2034).

Scope of the Age-related Macular Degeneration Market Report

* Coverage- 7MM
* Age-related Macular Degeneration Companies- Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
* Age-related Macular Degeneration Therapies- NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.
* Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration Market Barriers
* Age-related Macular Degeneration Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Age-related Macular Degeneration Unmet Needs, KOL's views, Analyst's views, Age-related Macular Degeneration Market Access and Reimbursement

Gain a strategic edge in the Age-related Macular Degeneration Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Age-related Macular Degeneration Market Forecast. Click here to lead in advancements @ Age-related Macular Degeneration Clinical Trials Assessment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Wet AMD Market Overview at a Glance

4. Dry AMD Market Overview at a Glance

5. Wet AMD Market: Future Perspective

6. Executive Summary

7. Key Events

8. Disease Background and Overview

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Drugs

12. Emerging Drugs of Wet AMD

13. Emerging Drugs of Dry AMD

14. AMD: Seven Major Market Analysis

15. Key Opinion Leaders' Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Market Access and Reimbursement of Wet AMD

20. Unmet Needs

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-market-size-was-usd-9500-million-in-2022-estimated-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Age-related Macular Degeneration Market Size was ~USD 9,500 Million in 2022, estimated DelveInsight here

News-ID: 3536791 • Views:

More Releases from ABNewswire

How J&J Accessories Uses Customer Behavior Analytics to Stay Ahead of Retail Trends
How J&J Accessories Uses Customer Behavior Analytics to Stay Ahead of Retail Tre …
In an era where many retailers struggle with excess inventory and declining margins, J&J Accessories has built a thriving e-commerce business by letting data guide every product decision. The company's analytical approach to understanding customer behavior has enabled it to maintain a fresh, relevant catalog that resonates with time-pressed professionals. This strategy positions the brand as a model for the next generation of agile online retail. The retail industry has long
Small Business Champion Rnispir LLC Showcases Products from Veteran and Women-Owned Enterprises Nationwide
Small Business Champion Rnispir LLC Showcases Products from Veteran and Women-Ow …
Rnispir LLC is making waves in the e-commerce sector by prioritizing partnerships with underrepresented business owners across America. With a network exceeding 400 U.S. suppliers, the company spotlights products from veterans, women entrepreneurs, and family operations, offering customers distinctive gourmet foods, outdoor equipment, and home goods unavailable through conventional retail channels. The American small business landscape faces unprecedented challenges, from supply chain disruptions to competition with multinational corporations. Rnispir LLC addresses
Dreambelles Revolutionizes Baby Clothing with Zipper Bodysuit Design That Opens Completely Flat
Dreambelles Revolutionizes Baby Clothing with Zipper Bodysuit Design That Opens …
Dreambelles is gaining recognition for solving a common parenting frustration with its patent-pending bodysuit featuring a full-front zipper that eliminates over-the-head dressing. The innovative design allows for mess-free, stress-free clothing and diaper changes while delivering the comfort and durability parents need. The earliest months and years of parenting involve constant repetition of basic care tasks, with dressing and diaper changes occurring numerous times daily. Despite this frequency, baby clothing design has
Why Taxpayers Are Turning to the Best Tax Return Software in UK
Why Taxpayers Are Turning to the Best Tax Return Software in UK
As HMRC continues to prioritise digital compliance, taxpayers are increasingly adopting software that supports their filing needs year-round, not just at deadline time. The best tax return software in UK reflects this shift, offering a blend of simplicity, transparency and precision. Pie's focus on accessibility and user experience underscores its mission: "It's your money. Claim it." LONDON, United Kingdom - As digital filing becomes the standard in the UK tax system,

All 5 Releases


More Releases for Macular

Elevated Diabetes Prevalence Fuels Growth In The Macular Edema And Macular Degen …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Macular Edema and Macular Degeneration Market Size By 2025? The market encompassing macular edema and macular degeneration has experienced substantial expansion recently, projected to increase from a value of $9.65 billion in 2024 to $10.33 billion in 2025, reflecting a compound annual growth rate (CAGR)
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts How Large Will the Macular Edema and Macular Degeneration Market Size By 2025? In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be? The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies. Download White Paper: https://www.towardshealthcare.com/download-statistics/5375 Market Overview and Key Drivers The macular
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033. Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance. The Market Size Is Expected To Reach $12.84
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The